Company News

2022-03-30
ImmuneOnco Announced Appointment of Dr. Xu, Wencheng as Vice President of Clinical Operations
On March 30, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xu, Wencheng as the vice president of clinical operations.
View more
2022-03-28
ImmuneOnco will share data in two posters at 2022 Annual Meeting of American Association for Cancer Research(AACR)
On March 28, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that data from 2 different new projects in two posters will be presented at the 2022 annual meeting of American Association for Cancer Research (AACR) hold in New Orleans from April 8 to 13.
View more
2022-03-21
Dr. Lu, Qiying joined ImmuneOnco as Chief Medical Officer (CMO) and Senior Vice President (SVP)
On March 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared the appointment of Dr. Lu Qiying was appointed as the chief medical officer and senior vice president of our Company in March 2022, and is responsible for formulating the clinical strategy and direct clinical development of our Group.
View more
2022-03-15
Dr. Xiong, Zikai joined ImmuneOnco as Senior Vice President(SVP)
On March 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xiong Zikai as the senior vice president (SVP) to be fully responsible for the company's BD affairs.
View more
2022-02-22
NMPA approved phase Ib/II clinical trial application of ImmuneOnco for IMM01 combined with PD-1 antibody in the treatment of relapsed and refractory malignant tumors
On February 22, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that National Medical Products Administration (NMPA) approved Phase Ib/II clinical trial application of the first domestic SIRPα-Fc fusion protein drug candidate targeting human CD47 (IMM01) combined with PD-1 antibody for the treatment of relapsed/ refractory malignant tumors.
View more
2022-02-15
IMM2902 of ImmuneOnco Completed the First Patient Dosing
February 15, 2022, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco", the company) announced that the first bispecific antibody-receptor recombinant protein (project number: IMM2902) targeting human CD47 x HER2 has completed the first patient enrollment and dosing, and administration process was smooth and successful.
View more
总计 53 123456789